Also, stroma-derived CCL2/CCL5 induces IL-6 release from the tumor cell generating carboplatin resistance through PYK2 pathway activation (positioned upstream of the JAK1/STAT3 pathway), a critical mediator of survival pathway activation (91). The gene discussed is CCL2; the disease is neoplasm.